Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years and life expectancy \>15 years * Any biopsy-proven WHO/ISUP grade groups III-V PCa * High-risk prostate cancer defined as: * Any biopsy-proven WHO/ISUP grade group III-V PCa or * ISUP grade group II and PSA \> 20 ng/ml * PSMA-PET: negative staging for regional and distant metastasis * multidisciplinary tumorboard recommendation for radical prostatectomy * WHO performance status 0-1 * Adequate condition (ASA ≤ III) for general anesthesia and RP Exclusion Criteria: * ISUP grade group I PCa and cT1 or cT2 (MRI) * cT4 (MRI) PCa * PSMA-PET: positive staging for local and distant metastasis * Any prior neoadjuvant, local or systemic treatment for PCa * Previous PLND or pelvic radiotherapy * Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence. * Any other serious underlying medical, psychiatric, psychological, familial, or geographical * condition, which in the judgment of the investigator may interfere with the planned * staging, treatment and follow-up, which affect patient compliance or place the patient at * high risk from treatment-related complications. * Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study.